This program is intended for hematologists, medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals who care for patients with CLL/SLL or MCL.
The goal of this program is to improve the knowledge, competence, and performance of learners to optimize treatment with BTK inhibitors in caring for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.
Upon completion of this activity, participants should be able to:
Evaluate differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration current indications, expert and guideline recommendations, and recent practice-changing clinical trial evidence
Implement evidence-based therapy for patients with resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
Optimally manage adverse events associated with BTKi-based therapies considering safety profiles unique to each agent and regimen
Identify patients with R/R MCL and R/R SLL/SLL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Division of Hematology/Oncology
Harold C. Simmons Compreshensive Cancer Center
University of Texas Southwestern Medical Center
Farrukh Awan, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotech, ADCT Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Cellecter Bioscience, Dava Oncology, Epizyme, Genentech, Genmab, Gilead, Incyte, Janssen, Johnson and Johnson, Karyopharm, Loxo Oncology, MEI Pharma, Merck, Pharmacyclics, Verastem; researcher: AbbVie, Pharmacyclics.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP and Susan J. Moench, PhD, PA-C, as noted below.
Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.
Susan J. Moench, PhD, PA-C: independent contractor: Gilead, Merck.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 14, 2023, through December 13, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-318-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 13, 2024. PAs should only claim credit commensurate with the extent of their participation.